US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.32

-0.1800-0.73%

Post-market: 24.320.00000.00%18:34 EDT

Volume:24.81K

Turnover:605.14K

Market Cap:56.42M

PE:- -

High:24.66

Open:24.66

Low:24.14

Close:24.50

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:0.52

T/O Rate:1.07%

Dividend:1.71

Dividend Rate:7.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment

Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing

THOMSON REUTERS

Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing

THOMSON REUTERS

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

SEG shares halted ahead of potential acquisition and capital raising

Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD), Surgery Partners (SGRY) and Apogee Therapeutics (APGE)

Upstream Bio reports Q2 revenue $773,000, consensus $377,250

PM Capital Global Opportunities Fund details non-underwritten capital raising

COMPASS Pathways (CMPS) Gets a Buy from Evercore ISI

MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results

Imagion Biosystems shareholders back capital raising and options at general meeting

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

RBC Capital Remains a Buy on GH Research (GHRS)

Analysts’ Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)

AbCellera to Report Phase 2 Menopause Therapy Data

Israel's Entera Bio Q2 Net Loss Widens

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)

NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/PSIL/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.32,"timestamp":1789588800000,"preClose":24.5,"halted":0,"volume":24809,"hourTrading":{"tag":"盘后","latestPrice":24.32,"preClose":24.32,"latestTime":"18:34 EDT","volume":35,"amount":854.7973,"timestamp":1789598075040,"change":0,"changeRate":0,"amplitude":0.007401},"delay":0,"changeRate":-0.007346938775510192,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Post-Mkt","change":-0.18,"latestTime":"09-16 18:43:18 EDT","open":24.66,"high":24.66,"low":24.14,"amount":605138.6471,"amplitude":0.021224,"askPrice":26.21,"askSize":10,"bidPrice":22.09,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":24.5,"sharesOutstanding":1184976,"nav":25.051,"aum":58118072.21,"dividendRate":0.070115,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.06,"preClose":24.5,"latestTime":"08:44 EDT","volume":39,"amount":972.7199820000001,"timestamp":1789562657590,"change":0.56,"changeRate":0.022857,"amplitude":0.039592},"postHourTrading":{"tag":"盘后","latestPrice":24.32,"preClose":24.32,"latestTime":"18:34 EDT","volume":35,"amount":854.7973,"timestamp":1789598075040,"change":0,"changeRate":0,"amplitude":0.007401},"volumeRatio":0.517577,"impliedVol":0.5167,"impliedVolPercentile":0.8645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.517577,"shares":2319976,"dividePrice":1.7052,"high":24.66,"amplitude":0.021224,"preClose":24.5,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.32,"committee":0.818182,"eps":0,"divideRate":0.070115,"volume":24809,"delay":0,"ttmEps":0,"open":24.66,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":25.21,"twentyDayClose":26.2,"sixtyDayClose":21.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658906555","title":"Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658906555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658906555?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:19","pubTimestamp":1786547988,"startTime":"0","endTime":"0","summary":"Alkermes cuts interest spreads on $1.52 billion term loan facilities via credit agreement amendmentAlkermes entered an amendment on Aug. 12, 2026 to its Feb. 12, 2026 credit agreement with JPMorgan Chase Bank.The deal covers senior secured term loan A of USD 745.31 million, due Feb. 12, 2031, and term loan B of USD 773.06 million, due Aug. 12, 2031.The amendment cuts the interest spread by 0.75% on the term loan A facility, 0.5% on the term loan B facility.Term loan A now prices at Term SOFR plus 1.75%-2.25%, or base rate plus 0.75%-1.25%, based on secured net leverage.Term loan B now prices at Term SOFR plus 2.25%, or base rate plus 1.25%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL3L5Jbs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU1720051017.SGD","LU0345770993.USD","JPX","FBT","LU1551013425.SGD","JPMO","LU0208291251.USD","IBRN","LU2357305700.SGD","TRUF","IE00BZ1G4Q59.USD","LU0211326755.USD","LU2552382132.HKD","FNCL","IXG","LU0320765646.SGD","UYG","LU2023250843.SGD","IYF","PSCH","JPO","KBWB","LU1629891620.HKD","LU0211331839.USD","LU0234572021.USD","LU2456880835.USD","LU0265550946.USD","LU0496365809.HKD","LU2462157665.USD","LU1116320901.HKD","LU1363072403.SGD","IE00BYXW3230.USD","LU0320765489.SGD","LU1162221912.USD","LU2552382215.SGD","PSIL","LU2054465674.USD","LU0106261372.USD","LU2237443622.USD","LU1974910355.USD","TFNS","FTXO","ALKS","MEDX","XLF","IYG","VFH","LU2505996681.GBP","LU1496350502.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908840","title":"Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908840?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","PSIL","FBT","PSCH","BK4139","MEDX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908808","title":"Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","IBRN","BK4139","FBT","PSIL","ALKS","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908647","title":"Altimmune Announces Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908647","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908647?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD  $519 million in cash, cas","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343554/0/en/altimmune-announces-second-quarter-2026-financial-results-and-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC","LU1242518931.SGD","BK4183","LU1978683503.SGD","IR","PSIL","LU1559883803.SGD","BK4585","LU0053671581.USD","LU0124384867.USD","LU0417517546.SGD","BK4161","LU0979878070.USD","LU0256863811.USD","ELF","BK4588","ALD","LU0256863902.USD","SG9999001440.SGD","LU0566484027.USD","CROC","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658941174","title":"SEG shares halted ahead of potential acquisition and capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2658941174","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658941174?lang=en_us&edition=fundamental","pubTime":"2026-08-12 07:23","pubTimestamp":1786490634,"startTime":"0","endTime":"0","summary":"An update from Sports Entertainment Group Limited ( ($AU:SEG) ) is now available. Sports Entertainment Group Limited has requested and been granted...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/seg-shares-halted-ahead-of-potential-acquisition-and-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/seg-shares-halted-ahead-of-potential-acquisition-and-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SEG","BK4233","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658433917","title":"Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD), Surgery Partners (SGRY) and Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658433917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658433917?lang=en_us&edition=fundamental","pubTime":"2026-08-12 02:10","pubTimestamp":1786471809,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Relmada Therapeutics (RLMD), Surgery Partners (SGRY) and Apogee T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-relmada-therapeutics-rlmd-surgery-partners-sgry-and-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-relmada-therapeutics-rlmd-surgery-partners-sgry-and-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4137","BK4588","SBIO","APGE","XLV","SGRY","LABU","BK4581","LU0029874061.USD","XBI","LU0053671581.USD","PSIL","BK4585","RLMD","BK4185","HCSG","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992421","title":"Upstream Bio reports Q2 revenue $773,000, consensus $377,250","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992421","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992421?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:15","pubTimestamp":1786446927,"startTime":"0","endTime":"0","summary":"“We continued to make progress toward the initiation of our Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027. Our End-of-Pha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-reports-q2-revenue-773000-consensus-377250-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-reports-q2-revenue-773000-consensus-377250-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950741","title":"PM Capital Global Opportunities Fund details non-underwritten capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658950741?lang=en_us&edition=fundamental","pubTime":"2026-08-11 07:36","pubTimestamp":1786405008,"startTime":"0","endTime":"0","summary":"PM Capital Global Opportunities Fund Ltd. ( ($AU:PGF) ) just unveiled an update. PM Capital Global Opportunities Fund Ltd. has outlined details of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pm-capital-global-opportunities-fund-details-non-underwritten-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pm-capital-global-opportunities-fund-details-non-underwritten-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4582","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939075","title":"COMPASS Pathways (CMPS) Gets a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939075?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:45","pubTimestamp":1786365933,"startTime":"0","endTime":"0","summary":"In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on COMPASS Pathways, with a price target of $21.00. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/compass-pathways-cmps-gets-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/compass-pathways-cmps-gets-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935473","title":"MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935473?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:50","pubTimestamp":1786362626,"startTime":"0","endTime":"0","summary":"07:45 EDT MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results Published first on TheFly – the ultimate source for real-tim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-shares-drop-11-pre-market-after-q2-earnings-phase-3-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-shares-drop-11-pre-market-after-q2-earnings-phase-3-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DECU","FEBU","VOTE","JOYT","PMDE","VGFPF","GXDW","RGLO","PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658160177","title":"Imagion Biosystems shareholders back capital raising and options at general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2658160177","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658160177?lang=en_us&edition=fundamental","pubTime":"2026-08-10 10:57","pubTimestamp":1786330641,"startTime":"0","endTime":"0","summary":"The latest update is out from Imagion Biosystems Ltd. ( ($AU:IBX) ). Imagion Biosystems Limited has reported the results of a general meeting at wh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/imagion-biosystems-shareholders-back-capital-raising-and-options-at-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/imagion-biosystems-shareholders-back-capital-raising-and-options-at-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GNMX","BK4007","GDOC","GNOM","HELX","LU0889565916.HKD","BK4539","PTH","BK4585","BK4551","BK4196","LU0320765992.SGD","PSIL","BK4535","LU0109394709.USD","GHRS","BK4588","LFSC","EKG","FFOX","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","GSIB","BK4207","BK4551","LU0310800379.SGD","LU1267930573.SGD","BK4196","EKG","GHRS","BK4585","FFOX","LU0128525929.USD","LU0320765992.SGD","BK4007","GDOC","LFSC","BK4588","LU0708994859.HKD","LU0889565916.HKD","PTH","GNMX","BK4539","LU0109394709.USD","HELX","BK4535","PSIL","GH","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657219266","title":"Analysts’ Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657219266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657219266?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:10","pubTimestamp":1786140605,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS) and Trulieve Cannabis (TRLV)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-compass-pathways-cmps-trulieve-cannabis-trlv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-compass-pathways-cmps-trulieve-cannabis-trlv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSOX","BK4581","YOLO","WEED","HCSG","MSOS","CMPS","XLV","BK4137","MJ","BK4007","LU0128526141.USD","TRLV","BK4588","LABU","BK4585","CNBS","PSIL","BK4139","XBI","LU0029874061.USD","TOKE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657292236","title":"AbCellera to Report Phase 2 Menopause Therapy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2657292236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657292236?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:19","pubTimestamp":1786137583,"startTime":"0","endTime":"0","summary":"AbCellera Biologics ( ($ABCL) ) has provided an update. On August 7, 2026, AbCellera announced it will release top-line data from its Phase 2 trial...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-to-report-phase-2-menopause-therapy-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-to-report-phase-2-menopause-therapy-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657488626","title":"Israel's Entera Bio Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657488626","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657488626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:31","pubTimestamp":1786134710,"startTime":"0","endTime":"0","summary":"CORRECTED-Israel's Entera Bio Q2 net loss widensCorrects period in Key Details to Q2, from H1OverviewIsrael oral peptide developer reported no revenue for Q2 2026Company's net loss widened due to high","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","GHRS","PSIL","DTIL","ENTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","BK4539","BK4585","PTH","FFOX","XLV","LU0128526141.USD","THNR","GNMX","EKG","LFSC","LU0109394709.USD","XBI","INMD","BK4581","BK4082","BK4007","PSIL","LABU","IBRN","GDOC","LU0320765992.SGD","BK4196","BK4588","HCSG","LU0889565916.HKD","BK4139","GH","LU0029874061.USD","HELX","SRRK","GHRS","BK4551","BK4535","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626537","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626537","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626537?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":"Conference Call 8:30 a.m. ET, Monday, August 10, 2026MIAMI, Aug.  07, 2026  (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341373/0/en/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-host-conference-call-august-10-to-discuss-fda-first-cycle-anda-review-and-commercial-plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQA","MNQmain","BK4588","QQQE","ONEQ","QYLG","NVIW.SI","NDX","HST","QQQM","QQQJ","PSIL","FTEC","TECS","BK4585","TQQY","LABU","NRXP","QQQY","BK4007","QID","GPIQ","SQQQ","QDTE",".IXIC","JEPQ","BK4181","TQQQ","QQQ","NQmain","PSQ","IYW","QLD","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640437","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657640437?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:30","pubTimestamp":1786120219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-nrx-pharmaceuticals-nrxp-novo-nordisk-nvo-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0225771236.USD","LU0225284248.USD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","PPH","SG9999002232.USD","SG9999013999.USD","LU0321505439.SGD","LU1883839398.USD","BK4534","IE0002270589.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU0122379950.USD","BK4007","BK4568","LU1066051498.USD","NVOH","LU0170899867.USD","BK4592","SG9999001176.USD","LU1066053197.SGD","LU0985481810.HKD","BK4585","SG9999001176.SGD","BK4533","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU1093756168.USD","LU0306806265.USD","IE00BLSP4452.SGD","LU0306807586.USD","LU2596442595.SGD","NRXP","IE000M9KFDE8.USD","SG9999003800.SGD","LU1023059063.AUD","LU1093756325.SGD","LU1894683348.USD","BK4550","BK4532","NVO","LU1057294990.SGD","LU0058720904.USD","PFE","NVOX","OZEM","PSIL","LU0321505868.SGD","BK4599","SG9999002224.SGD","LU0154236417.USD","LU0234572021.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU1894683264.USD","SG9999011175.SGD","BK4581","LU0868494617.USD","LU0456855351.SGD","THNR","BK4588","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657980640","title":"NRx Pharmaceuticals Shares Rise After FDA Finishes Ketamine Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657980640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657980640?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:24","pubTimestamp":1786119840,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals shares rose after the Food and Drug Administration completed its abbreviated new drug application review of the company's ketamine product.The stock climbed 21% to $3.73 on Friday. Shares are up 42% this year.The first-cycle review evaluated NRx's preservative-free ketamine and found no major deficiencies related to the product, ingredients or labeling, the drug company said Friday.The FDA did flag a remaining question related to the container closure of the medication vial. The issue is packaging-related and doesn't relate to the ketamine drug product itself, NRx said.The company is providing an attestation to the FDA related to the packaging issue.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","PSIL","NRXP","BK4585","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}